| Antioxidants in health, disease and aging M E Obrenovich, Y Li, K Parvathaneni, B B Yendluri, H H Palacios, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2011 | 140 | 2011 |
| Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration? K Gasiorowski, E Lamer-Zarawska, J Leszek, K Parvathaneni, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2011 | 125 | 2011 |
| Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals K Lederer, E Bettini, K Parvathaneni, MM Painter, D Agarwal, ... Cell 185 (6), 1008-1024. e15, 2022 | 119 | 2022 |
| Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease H H Palacios, B B Yendluri, K Parvathaneni, V B Shadlinski, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2011 | 79 | 2011 |
| Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo K Parvathaneni, DW Scott Blood advances 2 (18), 2332-2340, 2018 | 52 | 2018 |
| TGFβ induces BIGH3 expression and human retinal pericyte apoptosis: a novel pathway of diabetic retinopathy BS Betts-Obregon, AA Mondragon, AS Mendiola, RG LeBaron, R Asmis, ... Eye 30 (12), 1639-1647, 2016 | 32 | 2016 |
| Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4 VG Bhoj, L Li, K Parvathaneni, Z Zhang, S Kacir, D Arhontoulis, K Zhou, ... Molecular Therapy-Oncolytics 20, 387-398, 2021 | 28 | 2021 |
| Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation JG Grigsby, K Parvathaneni, MA Almanza, AM Botello, AA Mondragon, ... Journal of ocular pharmacology and therapeutics 27 (3), 225-233, 2011 | 22 | 2011 |
| Estrogen-induced retinal endothelial cell proliferation: possible involvement of pigment epithelium-derived factor and phosphoinositide 3-kinase/mitogen-activated protein … K Parvathaneni, JG Grigsby, BS Betts, AT Tsin Journal of ocular pharmacology and therapeutics 29 (1), 27-32, 2013 | 20 | 2013 |
| Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy M Uribe-Herranz, S Beghi, M Ruella, K Parvathaneni, S Salaris, ... Molecular Therapy 31 (3), 686-700, 2023 | 18 | 2023 |
| SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments K Parvathaneni, K Torres-Rodriguez, W Meng, WT Hwang, N Frey, A Naji, ... JAMA oncology, 2021 | 18 | 2021 |
| Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy K Parvathaneni, M Abdeladhim, KP Pratt, DW Scott Translational Research 187, 44-52, 2017 | 18 | 2017 |
| Ginsenoside‐Rb1 induces ARPE‐19 proliferation and reduces VEGF release BS Betts, K Parvathaneni, BB Yendluri, J Grigsby, ATC Tsin International Scholarly Research Notices 2011 (1), 184295, 2011 | 17 | 2011 |
| BIGH3 protein and macrophages in retinal endothelial cell apoptosis AA Mondragon, BS Betts-Obregon, RJ Moritz, K Parvathaneni, ... Apoptosis 20, 29-37, 2015 | 14 | 2015 |
| Genetic engineering of T cells for immune tolerance DW Scott Molecular Therapy-Methods & Clinical Development 16, 103-107, 2020 | 9 | 2020 |
| The role of sex hormones in diabetic retinopathy JG Grisby, DM Allen, RB Culbert, G Escobedo, K Parvathaneni, BS Betts Diabetic Retinopathy 17, 331-56, 2012 | 8 | 2012 |
| Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders-contemporary approaches A Sieradzki, B B Yendluri, H H Palacios, K Parvathaneni, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2011 | 8 | 2011 |
| BAR-CD8 T-cell mediated targeted killing of inhibitor producing FVIII-specific B cells K Parvathaneni, A Zhang, YC Kim, DW Scott Blood 126 (23), 294, 2015 | 7 | 2015 |
| Targeting antigen-specific B cells using BAR-transduced cytotoxic and regulatory T cells AH Zhang, K Parvathaneni, J Yoon, Y Kim, DW Scott The Journal of Immunology 196 (1_Supplement), 70.7-70.7, 2016 | 6 | 2016 |
| Adoptive immune responses to Sars-Cov2 vaccination in CART19 treated patients K Parvathaneni, K Toress-Rodriguez, W Meng, J Knox, X Xu, D Weiskopf, ... Blood 138 (Supplement 1), 1757-1757, 2021 | 3 | 2021 |
Gjumrakch AlievGALLY International Biomedical Research在 gallyinternational.com 的电子邮件经过验证
